Global Factor IX Deficiency Treatment Market 2017-2021
- SKU ID : TNV-IRTNTR12153 10543435
- |
- Publishing Date: 07-Mar-2017
- |
- Region: Global
- |
- No. of pages: 70
ABSTRACT
About Factor IX Deficiency Treatment
The global factor IX deficiency treatment market is characterized by the presence of various therapeutic products provided by some of the top vendors such as Shire, CSL Behring, Novo Nordisk, Biogen, and Pfizer. The adoption rate of therapeutics has undergone a paradigm shift toward the introduction of gene therapy, which will lead to the development of new products. However, the low penetration rate of recombinant therapy in developing countries is the current challenge in the market. This low penetration rate in developing countries is due to the higher cost of recombinant drugs, limited disease knowledge, and a shortage of treatment supplies. Nevertheless, the market has observed a positive side of individuals adopting recombinant drugs is expected to improve the diagnosis and treatment rates for hemophilia B in the medium- to long-term.
Technavio’s analysts forecast the global factor IX deficiency treatment market to grow at a CAGR of 5.12% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global factor IX deficiency treatment market for 2017-2021. To calculate the market size, the report considers the revenue generated from sales of factor IX products in the different diseases.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global Factor IX Deficiency Treatment Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• Biogen
• CSL Behring
• Novo Nordisk
• Pfizer
• Shire
Market driver
• Growing pipeline with increased focus to meet unmet demand.
• For a full, detailed list, view our report
Market challenge
• Emerging price war in the industry.
• For a full, detailed list, view our report
Market trend
• Increase in investments in the production and discovery.
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
About Factor IX Deficiency Treatment
The global factor IX deficiency treatment market is characterized by the presence of various therapeutic products provided by some of the top vendors such as Shire, CSL Behring, Novo Nordisk, Biogen, and Pfizer. The adoption rate of therapeutics has undergone a paradigm shift toward the introduction of gene therapy, which will lead to the development of new products. However, the low penetration rate of recombinant therapy in developing countries is the current challenge in the market. This low penetration rate in developing countries is due to the higher cost of recombinant drugs, limited disease knowledge, and a shortage of treatment supplies. Nevertheless, the market has observed a positive side of individuals adopting recombinant drugs is expected to improve the diagnosis and treatment rates for hemophilia B in the medium- to long-term.
Technavio’s analysts forecast the global factor IX deficiency treatment market to grow at a CAGR of 5.12% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global factor IX deficiency treatment market for 2017-2021. To calculate the market size, the report considers the revenue generated from sales of factor IX products in the different diseases.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global Factor IX Deficiency Treatment Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• Biogen
• CSL Behring
• Novo Nordisk
• Pfizer
• Shire
Market driver
• Growing pipeline with increased focus to meet unmet demand.
• For a full, detailed list, view our report
Market challenge
• Emerging price war in the industry.
• For a full, detailed list, view our report
Market trend
• Increase in investments in the production and discovery.
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
Please Select a Format
